SCHEMBL13336167

SCHEMBL13336167

C#Cc1ccc2nc(Nc3cc(CN4CCOCC4)cc(-c4cnn(C)c4)c3)ncc2c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.44
▸ KDR P35968 2/20 0.42
▸ CDK1 P06493 1/20 0.42
▸ JUN P05412 2/20 0.41
▸ MAPK10 P53779 2/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ CCNC P24863 4/20 0.39
▸ CDK8 P49336 4/20 0.39
▸ MET P08581 1/20 0.39
▸ MAP4K1 Q92918 2/20 0.39
▸ CDK19 Q9BWU1 2/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ AXL P30530 1/20 0.38
▸ MERTK Q12866 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ FGFR1 P11362 1/20 0.38
▸ FGFR4 P22455 1/20 0.38
▸ IGF1R P08069 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13363195 0.92 SYK (0.45) SYKKDRCDK1JUNMAPK10
SCHEMBL13336308 0.86 SYK (0.49) SYKKDRCDK1JUNMAPK10
SCHEMBL1570539 0.84 SYK (0.45) SYKKDRCDK1JUNMAPK10
SCHEMBL13336009 0.83 SYK (0.47) SYKKDRCDK1JUNMAPK10
SCHEMBL13336089 0.80 SYK (0.53) SYKKDRCDK1JUNMAPK10
SCHEMBL13336250 0.80 SYK (0.42) SYKKDRCDK1JUNMAPK10
SCHEMBL13336240 0.79 MAP4K1 (0.41) KDRCDK1METMAP4K1LRRK2
SCHEMBL13336093 0.78 MAP4K1 (0.52) SYKKDRCDK1JUNMAPK10
SCHEMBL13336248 0.77 SYK (0.44) SYKKDRCDK1JUNMAPK10
SCHEMBL13336034 0.77 MAP4K1 (0.42) SYKKDRCDK1JUNMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121052-A1 Novel compounds for treating proliferative diseases JAIN RAMA 2010-05-13 — — US disclosed
WO-2009153313-A1 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121052-A1 Novel compounds for treating proliferative diseases PDK1, PDK2, PDK3 SYK 4070/4885KDR 1028/4885CDK1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback